Lugtgener fra bilens ventilationsanlæg pga. akkumulering af bakterier og svamp er et velkendt problem, som kan have konsekvenser for sundhed og indeklima. ACD ApS har udviklet en innovativ løsning, ACD-Plugin, som er et lille UVC LED-lys i form af et plugin, tilpasset snævre og sværttilgængelige ventilationssystemer, som det der findes i biler. Den desinficerende effekt af UVC forstærkes af en antibakteriel TiO2-behandling, som med påvist effekt udraderer akkumulerede patogene.

ACOUPLAST aims to reach a 900M€/year market opportunity with the development of a polymer acoustofluidic chip for high-performing, fast and cost-effective plasma separation, to enable healthcare and veterinary Point-of-Care (PoC) diagnostics. Targeting life science companies, we will deliver AcouPlast chip modules for integration in single-use test cartridges. The solution is a recent research breakthrough by DTU Physics, experimentally validated by ACS, resulting in a patent application.

Akromegali er en sjælden sygdom forårsaget af øget niveauer af væksthormon, hvilket ofte er forårsaget af en godartet tumor i hypofysen. Flere studier peger på, at GIP receptoren (GIPR) kan forårsage de øgede væksthormonniveauer i en del af patienterne med akromegali. Vi er i den unikke situation, at vi har en GIPR antagonist, som kan bruges i mennesker. Med den vil vi klarlægge GIPRs involvering i akromegali og validere om GIPR antagonister kan bruges terapeutisk i denne patientgruppe.

We aim at developing a novel an innovative treatment opportunity for schizophrenia. Schizophrenia encompasses three different disease domains recognized as positive, negative and cognitive symptoms. Current medication is inadequate against negative and cognitive symptoms. By pursuing a novel target that has demonstrated promising preclinical result we aim at developing a new treatment paradigm for untreated symptoms in schizophrenia thereby covering a high unmet need.

Chronic pain affects more than 1.5 billion individuals globally – and is the single most prevalent symptom among geriatric patients. Chronic pain has tremendous impact on individuals’ wellbeing, lifestyle, independence, activity and comfort, and the condition is associated with the spiral degeneration of general quality of life of older adults, with increased disability, deconditioning and hence, increased change on frailty. ActiVITAE aims to help people ageing well by alleviating geriatric chronic pain using our completely novel and patented, ICT-based pain management system. The solution, Vibration Induced Treatment by Abdominal Excitation (VITAE), is disruptive and provides a pleasant, non-invasive Vagal Nerve Stimulation (VNS), utilising abdominal vibro-tactile stimulation of the Pacinian corpuscles.

The project goal is to bring to the clinical market and mass market an easily accessible, user-friendly and motivating digital medical device called (Alzheimer’s disease) AD Shield, delivered on tablets, smartphones and PCs/Mac. The main result will offer presymptomatic detection of AD and personalized AD prevention programs in the form of gamified cognitive training and behavioural interventions in one seamless product. The product targets citizens with the highest risk of AD (due to an acute unmet clinical need) and the healthcare professionals that serve these segments. OVERALL AMBITION: The goal is to create and become the global standard for presymptomatic AD care.

The project is concerned with research in adaptive learning algorithms, which will enable robots to react to variations in input, continuously perform corrections during operations and make adjustments to subsequent operations using feedback from the evaluation of the produced output. Additionally, the individual work process will make use of information collected along the production line in order to optimize its operation.

What is the innovation and the need behind the innovation?: AXIS will apply SotA artificial intelligence to automate the implementation of x-ray inspection systems. AXIS will automate classification software and the hardware specifications.; What is the most important competing solution?: No true competitors exist, a number of domain-specific competitors exist. We know of nobody that use AI for x-ray inspection.; Who will ultimately receive the value created?: Newtec, Qtechnology, and Magnatec all have business plans for the project results. ; What will the applied investment from Innovation Fund Denmark mainly be used for?: Research into a fully automated, x-ray based classification system, including x-ray equipment that works with the AI system.; How will the project results be implemented? Qtechnology and Magnatec will market components and Newtec will market full systems.

Projektet skaber ny viden om hvordan brugen af kompositte transparente materialer i en tæt urban kontekst bringer særlige lyskvaliteter ind i gade- og indendørs rum, og gestalter nogle nye forhold mellem inde og ude, mellem mennesker, naboer og bymiljø, og mellem kunst- og dagslys. Med IoT infrastruktur og software services opnår byens arkitektur nye indbyggede potentialer for adaptive funktioner, hvor kombinerede egenskaber af lyshed, skygge og transparens kan dynamisk tilpasses behov.

ADCendo ApS is a biotech spin-out established in 2017, with a vision to develop new anti-cancer drugs directed at a novel target, in the form of antibody-drug conjugates (ADCs). Current activities revolve around optimization of ADCendos first drug candidate, involving collaboration with international pharma companies. Thereby, this InnoBooster project will enable identification of a lead candidate, and contribute with key progress involving international knowledge- and technology providers.

In 40 years, only one drug, recently failed, has been approved for first-line therapy of sarcoma cancer. Through targeted therapy exploiting a novel antigen, ADCendo seeks to address this unmet need.

We propose cloud-based, personalised treatment to improve real-world adherence and outcomes for type 2 diabetes (T2D) patients. Adherence inhibits most T2D patients from reaching treatment targets. This impacts health, quality of life and cost society. To support care teams and empower patients to self-manage, we integrate data from continuous glucose monitors, connected insulin pens and activity trackers and provide real-time, personalised treatment guidance, data-derived insights, hypoglycemia warnings and dose reminders. Methods include large-scale data collection, development of a high-fidelity T2D model and required algorithms, and clinical feasibility testing of the full solution.

Insulin action in adipose tissue is central to metabolic control. Increases in fat mass can be driven by expansion of existing adipocytes or by recruitment of new adipocytes (adipogenesis). Preadipocytes are highly sensitive to insulin and IGF-1 in the differentiation process. This study will clarify the roles of InsR and IGF-1R in adipogenesis and provide important insights into the role of insulin in adipose tissue function, expansion and insulin sensitivity.

Med Adorno AR vil Adorno Digital tilbyde et produkt, hvormed designere, kunstenere, gallerier og deslignende kan få skabt 3D-modeller af deres værker, hvilket vil øge deres chancer for at sælge værkerne online signifikant. Dette påvises af 2 markedsundersøgelser udarbejdet af Adorno Digital. Adorno AR er et disruptivt produkt idet produktionen er betydeligt mere automatiseret, hvilket gør at produktionen af en 3D-model med Adorno AR er meget billigere og hurtigere, and andre på markedet.